Alnylam Pharmaceuticals Inc at Evercore HealthCONx Conference Transcript
Okay. Good afternoon, everyone. My name is Ravi Mehrotra. I'm a senior biotech analyst at Evercore ISI. It gives me great pleasure to have (inaudible) Jeff, President and CFO from Alnylam.
I have personally been looking forward to this fireside chat over all the 20 others that I've given, because Alnylam is a company which fits the most into our M2 thesis, which I'm sure most of you heard me talk about, and really trailblazed it for everyone else. We've now broken these down to Generation 1 and Generation 2. People forget just how long you guys have been doing this. So we're going to mix this fireside chat up a little bit. We're definitely going to talk about the assets, and we'll come on to some of the financial things. But I really want to start with this concept of M2. And (inaudible) really open to both of you to say, and you can criticize the thesis as much as you want or you can validate it as much as you want, but certainly, in my eyes, the modality is obvious. You were a pioneer in RNAi. The modularity
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
